Uckun Z.Baskak B.Ozdemir H.Ozelkizil E.T.Devrimci Ozguven H.Suzen H.S.2020-06-252020-06-2520161304530Xhttps://hdl.handle.net/20.500.12587/2497The objective of this study was to investigate the relationship between the genetic polymorphism of the serotonin transporter gene-linked polymorphic region (5-HTTLPR) and the response to citalopram treatment and side effects in Turkish patients with major depressive disorder. The study involved 51 patients who received 10-40 mg/day of citalopram for 4 to 6 weeks. Clinical symptoms were evaluated by the 17-item Hamilton Depression Rating (HAMD-17) scale, Clinical Global Impression (CGI) and UKU side effect rating scale (UKU) at weeks 4 and/or 6. The 5-HTTLPRL/S polymorphism was determined by slowdown-polymerase chain reaction method. Of the fifty-one patients, 13 (26%) were the LL genotype, 21 (41%) were the LS genotype, 17 (33%) were the SS genotype. L allele seems to be associated with better response due to odds ratio for L allele versus S allele despite statistically insignificant. In terms of CGI-Severity scale, The LL genotype versus the LS genotype had a higher risk at the week 6 (P<0.05). On the other hand, apart from this comparison, there is no significant difference in CGI-Severity and Improvement and UKU scales according to the distribution of genotypes at week 4 and/or 6. However, these findings surely need further investigation and confirmation. © 2016, Turkish Pharmacists Association. All rights reserved.eninfo:eu-repo/semantics/closedAccess5-HTTLPR polymorphismCitalopramSide effectsTreatment responseArticle1321451582-s2.0-84980022863Q2203609